SOURCE: Signature Diagnostics

October 20, 2010 15:00 ET

Signature Diagnostics to Present at Upcoming 2010 Life Science & Health Care Venture Summit in New York City

POTSDAM, GERMANY--(Marketwire - October 20, 2010) -


Signature Diagnostics /
Signature Diagnostics to Present at Upcoming 2010 Life Science & Health 
Care
Venture Summit in New York City
Processed and transmitted by Thomson Reuters.
The issuer is solely responsible for the content of this announcement.

Signature Diagnostics AG, a molecular diagnostics company, announced today that its CEO, André Rosenthal, has been selected to give a company presentation at the Life Science & Health Care Venture Summit conference on Thursday, October 21, 2010, in New York City.


About Signature Diagnostics AG

Signature Diagnostics AG is a molecular diagnostics company based in Potsdam, Germany, focusing on the development and commercialization of novel molecular oncology diagnostic products for early detection (screening) and prognosis of cancer. The company has completed development of its first two diagnostic products for colorectal cancer screening ("Detector C") and prognosis ("Predictor C"), which will be launched in early 2011 in its own ISO 15189 certified service laboratory. Using its state-of-the-art technologies in tissue and blood sample collection, molecular pathology, Xenopatient™ platform, genome-wide profiling, data mining, and biostatistics, the company collaborates with clinical, pharmaceutical, and diagnostic partners. Signature Diagnostics sponsors and conducts large prospective, multicenter clinical trials with more than 25 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers in oncology.



[HUG#1453723]



--- End of Message ---

Signature Diagnostics
Hermannswerder 20 A Potsdam Germany


Press release (PDF) : http://hugin.info/143237/R/1453723/394208.pdf




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Signature Diagnostics via Thomson Reuters ONE

Contact Information

  • For questions, please contact:

    Prof. Dr. Andre Rosenthal, CEO
    Signature Diagnostics
    Hermannswerder 20A
    14473 Potsdam, Germany
    Tel: 331-2000-208
    Email Contact